1. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10101 (23rd September 2017) Authors: McDonald, Craig M; Campbell, Craig; Torricelli, Ricardo Erazo; Finkel, Richard S; Flanigan, Kevin M; Goemans, Nathalie; Heydemann, Peter; Kaminska, Anna; Kirschner, Janbernd; Muntoni, Francesco; Osorio, Andrés Nascimento; Schara, Ulrike; Sejersen, Thomas; Shieh, Perry B; Sweeney, H Lee; Topaloglu... Journal: Lancet Issue: Volume 390:Issue 10101(2017) Page Start: 1489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects. Issue 2 (10th January 2019) Authors: Kong, Ronald; Laskin, Oscar L.; Kaushik, Diksha; Jin, Fengbin; Ma, Jiyuan; McIntosh, Joseph; Souza, Marcio; Almstead, Neil Journal: Clinical pharmacology in drug development Issue: Volume 8:Issue 2(2019) Page Start: 172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy. (25th September 2018) Authors: Thangarajh, Mathula; Elfring, Gary L.; Trifillis, Panayiota; McIntosh, Joseph; Peltz, Stuart W. Journal: Neurology Issue: Volume 91:Number 13(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗